Steven Horwitz
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Steven Horwitz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06698003 · A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1Memorial Sloan Kettering Cancer Center · recruiting · T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma, T-cell Leukemia · principal investigator
- N/ANCT05978141 · A Registry for People With T-cell LymphomaMemorial Sloan Kettering Cancer Center · recruiting · T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia · principal investigator
- Ph2NCT04101331 · Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis FungoidesAffimed GmbH · completed · Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides · principal investigator
- N/ANCT03964480 · Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.Associazione Angela Serra per la ricerca sul cancro · recruiting · Peripheral T-Cell Lymphoma · principal investigator
- Ph1NCT02783625 · Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasMemorial Sloan Kettering Cancer Center · completed · Lymphoma, Relapsed/Refractory T-cell Lymphomas · principal investigator
- Ph1/Ph2NCT02341014 · Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell LymphomasMemorial Sloan Kettering Cancer Center · completed · T-cell Lymphomas, Relapsed or Refractory · principal investigator
- Ph1/Ph2NCT01755975 · Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and MyelomaMemorial Sloan Kettering Cancer Center · completed · Multiple Myeloma, Non-Hodgkin's Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Communication Skills Intervention to Promote Transition into SurvivorshipR01CA151899 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2011 to 2015 · $587,964 awarded in 2015Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:17 UTC. The ranking covers the 200 most relevant of 102 PubMed records, and a shared surname and initials can bring in a namesake. All 102 on PubMed
- 623 citationsRCR 24.0
- Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.J Clin Oncol · 2012566 citationsRCR 14.1
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.Lancet Oncol · 2018563 citationsRCR 19.4
- Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.J Clin Oncol · 2011541 citationsRCR 14.1
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.J Clin Oncol · 2015472 citationsRCR 13.0
- 344 citationsRCR 12.3
- 310 citationsRCR 8.6
- Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.Blood · 2018255 citationsRCR 8.4
- 240 citationsRCR 16.7
- 229 citationsRCR 7.8